Last reviewed · How we verify
Oral Olanzapine
Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.
Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar I disorder (acute mania and maintenance), Agitation associated with schizophrenia or bipolar disorder.
At a glance
| Generic name | Oral Olanzapine |
|---|---|
| Also known as | ZYPREXA®, ZYPREXA, LY170053, Zyprexa |
| Sponsor | Eli Lilly and Company |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor, Serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Olanzapine antagonizes dopamine D2 receptors in the mesolimbic and mesocortical pathways, reducing positive symptoms of psychosis such as hallucinations and delusions. It also blocks serotonin 5-HT2A receptors and has activity at multiple other receptors (muscarinic, histamine H1, alpha-adrenergic), which contribute to its mood-stabilizing and anxiolytic effects. This multi-receptor profile distinguishes it from first-generation antipsychotics and provides efficacy across a broader range of psychiatric conditions.
Approved indications
- Schizophrenia
- Bipolar I disorder (acute mania and maintenance)
- Agitation associated with schizophrenia or bipolar disorder
- Adjunctive treatment of major depressive disorder
Common side effects
- Weight gain
- Sedation/somnolence
- Dizziness
- Hyperglycemia/diabetes
- Hyperlipidemia
- Akathisia
- Orthostatic hypotension
Key clinical trials
- An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC (PHASE4)
- Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting (PHASE3)
- A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Rolapitant and Palonosetron (NA)
- Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen (PHASE3)
- Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) (PHASE1, PHASE2)
- Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma (PHASE1)
- Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer (PHASE2)
- An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral Olanzapine CI brief — competitive landscape report
- Oral Olanzapine updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI